image: On July 9, the second day of the summit, Alex Zhavoronkov PhD, founder and CEO of Insilico Medicine, will be delivering a keynote titled “Generative AI for Drug Discovery, Longevity, and Sustainability: From Theory to Applications” from 14:20-14:40 local time, before participating in the panel discussion “Beyond human: AI, superhumans, and the quest for limitless performance & longevity” with David Sinclair, Professor of Genetics from Harvard Medical School.
Credit: Insilico Medicine
Known as the United Nations’ leading platform on artificial intelligence to solve global challenges, AI for Good Global Summit 2025 scheduled on July 8-11 will be held in Geneva, Switzerland as usual, hoping to advance the transformative potential of AI for the benefit of all. During the summit, leading contributors in the AI industry will be gathering and exchanging insights during, including Yoshua Bengio, Geoffrey Hinton, and Yann LeCun—otherwise known as the “godfathers of deep learning”.
On July 9, the second day of the summit, Alex Zhavoronkov PhD, founder and CEO of Insilico Medicine, will be delivering a keynote titled “Generative AI for Drug Discovery, Longevity, and Sustainability: From Theory to Applications” from 14:20-14:40 local time, before participating in the panel discussion “Beyond human: AI, superhumans, and the quest for limitless performance & longevity” with David Sinclair, Professor of Genetics from Harvard Medical School.
Founded in 2017 by the United Nations (UN) leading agency for digital technologies, AI for Good is currently thriving with over 37,000 active contributors spanning more than 180 countries, aiming to identify innovative AI applications, build skills and standards, and advance partnerships through more impact events across the globe.
Having invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for the generation of novel molecular structures with the desired properties and the generation of synthetic biological and patient data in 2014, Alex Zhavoronkov PhD has published over 200 peer-reviewed research papers and 3 books, and was nominated as one of the Clarivate Highly Cited Researchers multiple times.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.